Drug-eluting stents (DES) have demonstrated their superiority over bare-metal stents (BMS)
with respect to in-stent restenosis and the need for repeat revascularisation. BMS and first …

Drug eluting stents: maximising benefit and minimising cost | Heart Skip to main content
Viewing from: Google Indexer BMJ Journals Subscribe Log In More Log in via Institution Log in …

Drug delivery is central to modern cardiovascular care, where drug-eluting stents,
bioresorbable scaffolds, and drug-coated balloons all aim to restore perfusion while …

Since the advent of percutaneous coronary intervention (PCI) for stenosing coronary
disease, restenosis has remained a clinical problem. Despite the emergence and evolution …

Successful translation of new and innovative medical products from concept to clinical use is
a complex endeavor that requires understanding and overcoming a variety of challenges. In …

In the past few years, drug-eluting stents have emerged as one of the most promising
technologies in the field of interventional cardiology. Loaded with antiproliferative and anti …

Drug-eluting stents (DES) have become the standard of care for the treatment of coronary
artery disease. However, late stent thrombosis has emerged as a major concern, especially …

Drug-eluting stents are cardiovascular stents able to release a medical drug after
implantation. The medical drug is, in general, aimed at healing the vascular tissues injured …

Permanent metallic stents are associated with limitations such as continued mechanical
stress, transfer to the tissue, and continued biological interaction with the surrounding tissue …

Background Innovations in drug eluting stent designs make it increasingly important to
develop models for differentiating performance through spatial definition of drug, receptor …